Anti-doping-2024
ID: 353908Type: Posted
Overview

Buyer

Office of National Drug Control Policy (ONDCP)

Award Range

$14M - $14M

Eligible Applicants

Nonprofits Without 501(c)(3) Status

Funding Category

Law, Justice and Legal Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353908

Additional Information

https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=111096
Timeline
    Description

    The Office of National Drug Control Policy (ONDCP) is inviting applications for the "Anti-doping-2024" grant, aimed at supporting anti-doping activities that educate athletes about the dangers of drug use and work to eliminate doping in amateur athletic competitions recognized by the United States Olympic and Paralympic Committee. Eligible applicants must be recognized by the United States Olympic and Paralympic Committee as the official anti-doping agency and must coordinate with other anti-doping organizations. The grant has a total funding amount of $14 million, with one award anticipated, and applications are due by May 31, 2024. For further inquiries, applicants can contact the Grants.gov Customer Support at support@grants.gov or call 1-800-518-4726.

    Point(s) of Contact
    support@grants.gov
    Files
    No associated files provided.
    Similar Opportunities
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)." This initiative invites Small Business Technology Transfer (STTR) grant applications from small business concerns proposing research projects aimed at developing innovative, FDA-regulated medical products to address the urgent needs of patients suffering from opioid and stimulant use disorders. The program is particularly focused on two scientific areas: pharmacotherapeutics and medical therapeutic and diagnostic devices, including software as a medical device, in response to the national crisis of substance use disorders. Grants of up to $300,000 are available, with a submission deadline of February 14, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement grant titled "Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose." This funding opportunity aims to support research that evaluates prevention strategies aimed at reducing nonfatal and fatal overdoses, particularly among populations at higher risk due to social determinants of health. The initiative is crucial for addressing the ongoing public health crisis related to drug overdoses and substance use disorders, especially among youth. The estimated total program funding is $4.9 million, with an award ceiling of $700,000 and an expected seven awards to be made. Interested applicants must submit their proposals electronically by December 2, 2024, and can direct inquiries to Candis M. Hunter at ncipcerpo@cdc.gov.
    Disaster Recovery National Dislocated Worker Grants to Address the Opioid Crisis
    Active
    Employment and Training Administration
    The Employment and Training Administration of the U.S. Department of Labor is offering National Dislocated Worker Grants aimed at addressing the opioid crisis through disaster recovery initiatives. Eligible applicants, including states, outlying areas, and Indian tribal governments, are encouraged to submit proposals that detail their funding requests, projected participant numbers, and the activities they plan to implement, focusing on job creation and training related to opioid recovery. This funding opportunity, with an estimated total program funding of $100 million and an award ceiling of $100 million, aims to support community resilience and recovery efforts, with applications due by October 31, 2024. For inquiries, applicants can contact Anu Mathew at DOL-ETA-DWG@dol.gov.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Small Business Innovation Research (SBIR) grants aimed at developing regulated therapeutic and diagnostic solutions for patients affected by Opioid Use Disorders (OUD) and Stimulant Use Disorders (StUD). This initiative encourages small businesses to propose research projects focused on the commercialization of novel, FDA-regulated medical products, specifically in the areas of pharmacotherapeutics and medical therapeutic and diagnostic devices, including software solutions. Given the urgent public health crisis highlighted by rising drug overdose fatalities, this funding aims to enhance treatment accessibility and efficacy for affected individuals and communities. Interested applicants can apply for a total funding amount of approximately $3 million, with a submission deadline of February 14, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.